lower gi drugs katzung (10th ed.) chapter 63: pg. 1019-1036 med 5724 gastrointestinal hepatobiliary...
TRANSCRIPT
![Page 1: Lower GI Drugs Katzung (10th ed.) Chapter 63: pg. 1019-1036 Med 5724 Gastrointestinal Hepatobiliary System Winter 2009 Dr. Janet Fitzakerley jfitzake@d.umn.edu](https://reader035.vdocuments.us/reader035/viewer/2022062321/56649e105503460f94afaecc/html5/thumbnails/1.jpg)
Lower GI DrugsKatzung (10th ed.) Chapter 63: pg. 1019-1036
Med 5724 Gastrointestinal Hepatobiliary System
Winter 2009
Dr. Janet Fitzakerley [email protected]
http://www.d.umn.edu/~jfitzake/Lectures/Teaching.html
![Page 2: Lower GI Drugs Katzung (10th ed.) Chapter 63: pg. 1019-1036 Med 5724 Gastrointestinal Hepatobiliary System Winter 2009 Dr. Janet Fitzakerley jfitzake@d.umn.edu](https://reader035.vdocuments.us/reader035/viewer/2022062321/56649e105503460f94afaecc/html5/thumbnails/2.jpg)
Critical Facts
1. Many of the drugs that affect lower GI function work by modulating the actions of the enteric nervous system. The neurotransmitters acetylcholine (ACh), serotonin (5HT3), dopamine and the enkephalins are the important regulators of motility and water absorption (from a pharmacologist’s perspective!).
2. METOCLOPRAMIDE and CISAPRIDE act as cholinomimetics to increase GI motility. CISAPRIDE has severe side effects (fatal arrhythmias) that restrict its use.
3. The opiates LOPERAMIDE and DIPHENOXYLATE decrease both GI motility and water excretion, and are the most effective antidiarrheal drugs. They can be distinguished by the degree of their CNS penetration. LOPERAMIDE is available OTC because it has very little potential for addiction.
4. Several antidiarrheal agents have very limited uses: BILE ACID BINDING RESINS for diseases of the terminal ileum or surgical resection resulting in decreased bile salt reabsorption; OCTREOTIDE for dumping syndrome, short bowel disease, etc. and BISMUTH SUBSALICYLATE for traveler’s diarrhea.
5. MINERAL OIL (a stool softener) can cause severe lipid pneumonitis if aspirated; long term use may result in decreased absorption of fat soluble vitamins.
6. BISACODYL and ANTHRAQUINONES act on the large intestine and are less potent. CASTOR OIL acts on both the small and large intestine short latency and extremely potent effects --- as well as more significant side effects.
7. Osmotic laxatives (LACTULOSE, MAGNESIUM HYDROXIDE) can cause intravascular volume depletion and electrolyte imbalances, esp. reduced potassium concentrations (therefore contraindicated in patients who are frail, elderly, have renal insufficiency or have significant cardiac disease).
8. Prescription of laxatives should be secondary to dietary modifications, increasing fluid intake and physical activity. Patients can become reliant on a daily laxative dose (cathartic colon).
![Page 3: Lower GI Drugs Katzung (10th ed.) Chapter 63: pg. 1019-1036 Med 5724 Gastrointestinal Hepatobiliary System Winter 2009 Dr. Janet Fitzakerley jfitzake@d.umn.edu](https://reader035.vdocuments.us/reader035/viewer/2022062321/56649e105503460f94afaecc/html5/thumbnails/3.jpg)
Learning Objectives
1. Describe the neurotransmitters of the enteric nervous system that are key to understanding pharmaceutical treatment of diarrhea and constipation (paying particular attention to the role of serotonin). Be able to 1) name agonists and antagonists that act on each neurotransmitter system, and 2) differentiate among the specific therapeutic uses for those drugs.
2. Describe the mechanism of action and side effects of drugs that increase GI motility. Differentiate between prokinetics and laxative/cathartics. Identify the reason that CISAPRIDE is restricted in its availability.
3. Describe the mechanisms of action of antidiarrheal agents and relate these to their side effects. Be able to identify the specific types of diarrhea that BILE ACID BINDING RESINS, OCTREOTIDE, and BISMUTH SUBSALICYLATE are used to treat.
4. Be able to differentiate among laxatives and cathartics with respect to mechanisms of action, potency, latency and side effects.
![Page 4: Lower GI Drugs Katzung (10th ed.) Chapter 63: pg. 1019-1036 Med 5724 Gastrointestinal Hepatobiliary System Winter 2009 Dr. Janet Fitzakerley jfitzake@d.umn.edu](https://reader035.vdocuments.us/reader035/viewer/2022062321/56649e105503460f94afaecc/html5/thumbnails/4.jpg)
Important Material from Other Lectures
1. Physiology of GI motility and defecation, function of the enteric nervous system and mechanism of water and electrolyte transport in the GI tract (Dr. Heller, GIHBS)
2. Macrolide antibiotics (Dr. Regal, Principles)
3. Opiates and dopamine antagonists (Dr. Eisenberg, Nervous System)
4. Drugs affecting the autonomic nervous system (Dr. Trachte, CV and Nervous systems)
5. Bile Acid Binding Resins (Dr. Trachte, CV)
![Page 5: Lower GI Drugs Katzung (10th ed.) Chapter 63: pg. 1019-1036 Med 5724 Gastrointestinal Hepatobiliary System Winter 2009 Dr. Janet Fitzakerley jfitzake@d.umn.edu](https://reader035.vdocuments.us/reader035/viewer/2022062321/56649e105503460f94afaecc/html5/thumbnails/5.jpg)
Drugs You Need to KnowIncrease GI Motility
(Prokinetics) Antidiarrheals
CISAPRIDE Propulsid Opiates Absorbants
MACROLIDE ANTIBIOTICS e.g., ERYTHROMYCIN
DIPHENOXYLATE Lomotil
KAOLIN/PECTIN KaoPectate
METOCLOPRAMIDE Reglan
LOPERAMIDE Imodium
Bile Acid Binding Resins
Miscellaneous
CHOLESTYRAMINE Questrin
BISMUTH SUBSALICYLATE Peptobismol
COLESTIPOL Colestid, Colestitabs
OCTREOTIDE Sandostatin
Laxatives and Cathartics
Stool softeners Contact cathartics Osmotic cathartics
DOCUSATE Aqualax, Calube, Colace, Colace Micro-Enema, Correctol Softgel Extra Gentle, DC-240, Dialose, Diocto, Dioctocal, Dioctosoftez, Dioctyn, Dionex, Doc-Q-Lace, Docu Soft, Docucal, Doculax, Docusoft S, DOK, DOS, Doss-Relief, DSS, Dulcolax, Ex-Lax Stool Softener, Fleet Sof-Lax, Genasoft, Kasof, Modane Soft, Octycine-100, Regulax SS, Sulfalax Calcium, Sur-Q-Lax, Surfak Stool Softener and Therevac-SB
ANTHRAQUINONE DERIVATIVES CASACARA SAGRADA, DANTHRON, SENNA
BISACODYL Alophen, Carter's Little Pills, Correctol, Dulcolax, Fleet
CASTOR OIL
LACTULOSE Cephulac
LUBIPROSTONE Amitiza MAGNESIUM HYDROXIDE Milk of Magnesia
Bulk laxatives SODIUM PHOSPHATE
DIETARY FIBER Fleet enema, OsmoPrep, Vicol, Wal-phosphate
METHYLCELLULOSE Celoftel, Citrocel
POLYETHYLENE GLYCOL SOLUTION
PSYLLIUM Metamucil
Miralax, GoLytely, GlycoLax, CoLyte, NuLytely
- also see GI Decontamination handout
![Page 6: Lower GI Drugs Katzung (10th ed.) Chapter 63: pg. 1019-1036 Med 5724 Gastrointestinal Hepatobiliary System Winter 2009 Dr. Janet Fitzakerley jfitzake@d.umn.edu](https://reader035.vdocuments.us/reader035/viewer/2022062321/56649e105503460f94afaecc/html5/thumbnails/6.jpg)
Review of Large Intestine Physiology
• motility and water absorption are often treated as separate processes, but they are interrelated (e.g., increasing transit time increases water absorption) - many drugs affect both processes
• the enteric nervous system can regulate GI motility and secretion independent of extrinsic sympathetic and parasympathetic input
Many of the drugs that affect lower GI function work by modulating the actions of the enteric nervous system. The neurotransmitters acetylcholine (ACh), serotonin, dopamine and the enkephalins are the important regulators of motility and water absorption (from a
pharmacologist’s perspective!).
![Page 7: Lower GI Drugs Katzung (10th ed.) Chapter 63: pg. 1019-1036 Med 5724 Gastrointestinal Hepatobiliary System Winter 2009 Dr. Janet Fitzakerley jfitzake@d.umn.edu](https://reader035.vdocuments.us/reader035/viewer/2022062321/56649e105503460f94afaecc/html5/thumbnails/7.jpg)
PHARMACOLOGICALLY SIGNIFICANT NEUROTRANSMITTER ACTIONS
GI DRUG and ACTION
ACETYLCHOLINE (M) increases motility
increases water excretion (decreases absorption)
ANTAGONISTS: ATROPINE
SEROTONIN 5HT1 increases water absorption by increasing NANC-
mediated inhibition of water excretion 5HT3 increases distal relaxation by exciting NANC
neurons 5HT4 increases proximal contraction
5HT3 ANTAGONISTS: ALOSETRON, DOLASETRON,
GRANISETRON, ONDANSETRON
5HT4 AGONISTS: CISAPRIDE, TEGASEROD
DOPAMINE (D2) decreases ACh-induced motility
ANTAGONISTS: METOCLOPRAMIDE, Domperidone
ENKEPHALINS μ stimulates 5HT1 increase in water absorption κ and μ inhibit ACh-induced motility
AGONISTS: DIPHENOXYLATE, LOPERAMIDE
![Page 8: Lower GI Drugs Katzung (10th ed.) Chapter 63: pg. 1019-1036 Med 5724 Gastrointestinal Hepatobiliary System Winter 2009 Dr. Janet Fitzakerley jfitzake@d.umn.edu](https://reader035.vdocuments.us/reader035/viewer/2022062321/56649e105503460f94afaecc/html5/thumbnails/8.jpg)
NA, VIP,or otherNA, VIP,or other
NANC5HT3
-
NANC5HT3
NANC5HT35HT3
--
ACh
+
ACh
+
-
+
5HT4
++
5HT4
5HT1or2
5-HT
++
+
5-HT
++
5-HT
+
5-HT5-HT5-HT5-HT
++
+
ACh
Enk
+
EnkEnk
+
EnkEnk
,--DA- DADA-D2D2
PERISTALTIC REFLEX
ProximalContraction
DistalRelaxation
WATEREXCRETION
![Page 9: Lower GI Drugs Katzung (10th ed.) Chapter 63: pg. 1019-1036 Med 5724 Gastrointestinal Hepatobiliary System Winter 2009 Dr. Janet Fitzakerley jfitzake@d.umn.edu](https://reader035.vdocuments.us/reader035/viewer/2022062321/56649e105503460f94afaecc/html5/thumbnails/9.jpg)
Serotonin
• Here is what I hope is a simplified --- and understandable --- explanation for the effects of 5HT3 antagonists and 5HT4 agonists.
• It is becoming increasingly clear that serotonin plays a critical role in the pathophysiology of the lower GI tract (particularly in IBS). 5HT acts by altering sensory afferent activity, as well as by altering cholinergic and non-adrenergic, non-cholinergic (NANC) nerve activity, both directly and via reflex loops.
• One of the major roles for serotonin in the gut is thought to be regulation of the peristaltic reflex, which consists of both PROXIMAL CONTRACTION and DISTAL RELAXATION. In both cases, 5HT primarily acts on vagal afferents, which subsequently invoke a complicated reflex loop (which I simplified considerably by having the 5HT “neuron” act directly on the ACh and NANC neurons in your diagram). It’s also important to consider that the phrases “smooth muscle contraction” and “GI motility” (i.e., co-coordinated muscle contractions) are not necessarily synonymous.
![Page 10: Lower GI Drugs Katzung (10th ed.) Chapter 63: pg. 1019-1036 Med 5724 Gastrointestinal Hepatobiliary System Winter 2009 Dr. Janet Fitzakerley jfitzake@d.umn.edu](https://reader035.vdocuments.us/reader035/viewer/2022062321/56649e105503460f94afaecc/html5/thumbnails/10.jpg)
Serotonin (cont’d)
• First, the easier to understand stuff. PROXIMALLY, stimulation of 5HT4 receptors stimulation of vagal afferents activation of interneurons containing ACh and/or CGRP stimulation of ACh motoneurons increased contractility.
• Therefore, administration of 5HT4 agonists (like CISAPRIDE and TEGASEROD) promote gastric emptying and speed up intestinal transit by stimulating ACh-containing motor neurons ( good things for the treatment of constipation-predominant IBS).
![Page 11: Lower GI Drugs Katzung (10th ed.) Chapter 63: pg. 1019-1036 Med 5724 Gastrointestinal Hepatobiliary System Winter 2009 Dr. Janet Fitzakerley jfitzake@d.umn.edu](https://reader035.vdocuments.us/reader035/viewer/2022062321/56649e105503460f94afaecc/html5/thumbnails/11.jpg)
Serotonin (cont’d)
• Now for the tough stuff. DISTALLY, stimulation of 5HT3 receptors stimulation of vagal afferents activation of interneurons containing nitric oxide or VIP inhibition of ACh motoneurons decreased contractility passage of food bolus.
• This means that administration of 5HT3 antagonists (like ONDANSETRON and ALSOETRON) increase distal contraction, which interferes with the timing of the peristaltic reflex. The net result of this is a decrease in the “effectiveness” of colonic motility and an increase in total transit time ( benefits for the treatment of diarrhea-predominant IBS). During vomiting, interference with reverse peristalsis is thought to be due to a similar interruption in effective segmentation.
![Page 12: Lower GI Drugs Katzung (10th ed.) Chapter 63: pg. 1019-1036 Med 5724 Gastrointestinal Hepatobiliary System Winter 2009 Dr. Janet Fitzakerley jfitzake@d.umn.edu](https://reader035.vdocuments.us/reader035/viewer/2022062321/56649e105503460f94afaecc/html5/thumbnails/12.jpg)
Serotonin Bottom Line
• ABSOLUTE BOTTOM LINE:
• 5HT4 agonists increase GI motility (decrease transit time)
• 5HT3 antagonists increase contractility but decrease co-ordination(increase transit time)
![Page 13: Lower GI Drugs Katzung (10th ed.) Chapter 63: pg. 1019-1036 Med 5724 Gastrointestinal Hepatobiliary System Winter 2009 Dr. Janet Fitzakerley jfitzake@d.umn.edu](https://reader035.vdocuments.us/reader035/viewer/2022062321/56649e105503460f94afaecc/html5/thumbnails/13.jpg)
Drugs Causing Constipation or Diarrhea
• many drugs produce diarrhea, constipation or both as adverse side effects
• drugs produce adverse lower GI effects by altering:o cholinergic transmission o osmolarity of the digestive system contents
o GI motility • obviously, these mechanisms can overlap
![Page 14: Lower GI Drugs Katzung (10th ed.) Chapter 63: pg. 1019-1036 Med 5724 Gastrointestinal Hepatobiliary System Winter 2009 Dr. Janet Fitzakerley jfitzake@d.umn.edu](https://reader035.vdocuments.us/reader035/viewer/2022062321/56649e105503460f94afaecc/html5/thumbnails/14.jpg)
Drugs affecting cholingergic transmission
• Inhibiting transmission (contstipating): anticholinergics, antihistamines, antiParkinonian drugs, clonidine, ganglionic blocking agents, phenothiazines, tricyclic antidepressants
• Facilitating transmission (producing diarrhea): adrenergic ganglionic blocking agents, cholinergic agonists and cholinesterase inhibitors, prostaglandins, quinidine
![Page 15: Lower GI Drugs Katzung (10th ed.) Chapter 63: pg. 1019-1036 Med 5724 Gastrointestinal Hepatobiliary System Winter 2009 Dr. Janet Fitzakerley jfitzake@d.umn.edu](https://reader035.vdocuments.us/reader035/viewer/2022062321/56649e105503460f94afaecc/html5/thumbnails/15.jpg)
Drugs affecting water reabsorption
• Increasing reabsorption (contstipating): aluminum hydroxide
• Decreasing reabsorption (producing diarrhea): magnesium hydroxide, diuretics that cause hypokalemia, heavy metals
(esp. lead), iron, antidiarrheals
![Page 16: Lower GI Drugs Katzung (10th ed.) Chapter 63: pg. 1019-1036 Med 5724 Gastrointestinal Hepatobiliary System Winter 2009 Dr. Janet Fitzakerley jfitzake@d.umn.edu](https://reader035.vdocuments.us/reader035/viewer/2022062321/56649e105503460f94afaecc/html5/thumbnails/16.jpg)
Drugs affecting GI motility
• Decreasing motility (contstipating): monoamine oxidase inhibitors, muscle relaxants, opioids, verapamil
• Increasing motility (producing diarrhea): macrolide antibiotics, osmotic and contact cathartics, prokinetic agents
![Page 17: Lower GI Drugs Katzung (10th ed.) Chapter 63: pg. 1019-1036 Med 5724 Gastrointestinal Hepatobiliary System Winter 2009 Dr. Janet Fitzakerley jfitzake@d.umn.edu](https://reader035.vdocuments.us/reader035/viewer/2022062321/56649e105503460f94afaecc/html5/thumbnails/17.jpg)
DRUGS THAT INCREASE GI MOTILITY (PROKINETICS)
METOCLOPRAMIDE, CISAPRIDE,
MACROLIDE ANTIBIOTICS
![Page 18: Lower GI Drugs Katzung (10th ed.) Chapter 63: pg. 1019-1036 Med 5724 Gastrointestinal Hepatobiliary System Winter 2009 Dr. Janet Fitzakerley jfitzake@d.umn.edu](https://reader035.vdocuments.us/reader035/viewer/2022062321/56649e105503460f94afaecc/html5/thumbnails/18.jpg)
CHOLINOMIMETICS:METOCLOPRAMIDE, CISAPRIDE
METOCLOPRAMIDE and CISAPRIDE act as cholinomimetics to increase GI motility. CISAPRIDE has severe side effects (fatal arrhythmias) that restrict its use.
![Page 19: Lower GI Drugs Katzung (10th ed.) Chapter 63: pg. 1019-1036 Med 5724 Gastrointestinal Hepatobiliary System Winter 2009 Dr. Janet Fitzakerley jfitzake@d.umn.edu](https://reader035.vdocuments.us/reader035/viewer/2022062321/56649e105503460f94afaecc/html5/thumbnails/19.jpg)
CHOLINOMIMETICS:METOCLOPRAMIDE, CISAPRIDE
Mechanisms of action
+
5HT4
ACh
+
5HT4
++
5HT4
ACh
ACh
+
ACh
+
ACh
+
D2
DA-X
![Page 20: Lower GI Drugs Katzung (10th ed.) Chapter 63: pg. 1019-1036 Med 5724 Gastrointestinal Hepatobiliary System Winter 2009 Dr. Janet Fitzakerley jfitzake@d.umn.edu](https://reader035.vdocuments.us/reader035/viewer/2022062321/56649e105503460f94afaecc/html5/thumbnails/20.jpg)
CHOLINOMIMETICS:METOCLOPRAMIDE, CISAPRIDE
Therapeutic Uses
![Page 21: Lower GI Drugs Katzung (10th ed.) Chapter 63: pg. 1019-1036 Med 5724 Gastrointestinal Hepatobiliary System Winter 2009 Dr. Janet Fitzakerley jfitzake@d.umn.edu](https://reader035.vdocuments.us/reader035/viewer/2022062321/56649e105503460f94afaecc/html5/thumbnails/21.jpg)
CHOLINOMIMETICS:METOCLOPRAMIDE, CISAPRIDE
Side Effects
![Page 22: Lower GI Drugs Katzung (10th ed.) Chapter 63: pg. 1019-1036 Med 5724 Gastrointestinal Hepatobiliary System Winter 2009 Dr. Janet Fitzakerley jfitzake@d.umn.edu](https://reader035.vdocuments.us/reader035/viewer/2022062321/56649e105503460f94afaecc/html5/thumbnails/22.jpg)
MACROLIDE ANTIBIOTICS (e.g., erythromycin) stimulate motilin receptors on GI smooth muscle initiation of migrating motor complex
odoses that are subclinical for antibiotic actions will produce significant increases in GI motility
oHOWEVER, these lower doses are sufficient to produce resistance; therefore, use of MACROLIDES solely for GI effects is controversial
![Page 23: Lower GI Drugs Katzung (10th ed.) Chapter 63: pg. 1019-1036 Med 5724 Gastrointestinal Hepatobiliary System Winter 2009 Dr. Janet Fitzakerley jfitzake@d.umn.edu](https://reader035.vdocuments.us/reader035/viewer/2022062321/56649e105503460f94afaecc/html5/thumbnails/23.jpg)
ANTIDIARRHEALS
• all are safely used in patients with mild to moderate acute diarrhea
• should not be used in patients with bloody diarrhea, high fever or systemic toxicity because of the risk of exacerbating the underlying condition - should be discontinued if the diarrhea is worsening despite therapy
![Page 24: Lower GI Drugs Katzung (10th ed.) Chapter 63: pg. 1019-1036 Med 5724 Gastrointestinal Hepatobiliary System Winter 2009 Dr. Janet Fitzakerley jfitzake@d.umn.edu](https://reader035.vdocuments.us/reader035/viewer/2022062321/56649e105503460f94afaecc/html5/thumbnails/24.jpg)
Types
![Page 25: Lower GI Drugs Katzung (10th ed.) Chapter 63: pg. 1019-1036 Med 5724 Gastrointestinal Hepatobiliary System Winter 2009 Dr. Janet Fitzakerley jfitzake@d.umn.edu](https://reader035.vdocuments.us/reader035/viewer/2022062321/56649e105503460f94afaecc/html5/thumbnails/25.jpg)
1) OPIATES: DIPHENOXYLATE, LOPERAMIDE
The opiates LOPERAMIDE and DIPHENOXYLATE decrease both GI motility and water excretion, and are the most effective antidiarrheal drugs. They can be distinguished by the degree of their CNS penetration. LOPERAMIDE is available OTC because it has very little potential for addiction.
![Page 26: Lower GI Drugs Katzung (10th ed.) Chapter 63: pg. 1019-1036 Med 5724 Gastrointestinal Hepatobiliary System Winter 2009 Dr. Janet Fitzakerley jfitzake@d.umn.edu](https://reader035.vdocuments.us/reader035/viewer/2022062321/56649e105503460f94afaecc/html5/thumbnails/26.jpg)
1) OPIATES: DIPHENOXYLATE, LOPERAMIDE
Mechanism of Action
NA, VIP,or otherNA, VIP,or other
ACh
+
ACh
+
-
+
5HT4
++
5HT4
5HT1or2
5-HT
+
+
ACh
Enk
+
EnkEnk
+
EnkEnk
,--
![Page 27: Lower GI Drugs Katzung (10th ed.) Chapter 63: pg. 1019-1036 Med 5724 Gastrointestinal Hepatobiliary System Winter 2009 Dr. Janet Fitzakerley jfitzake@d.umn.edu](https://reader035.vdocuments.us/reader035/viewer/2022062321/56649e105503460f94afaecc/html5/thumbnails/27.jpg)
1) OPIATES: DIPHENOXYLATE, LOPERAMIDE
Side effects
Functional effects associated withthe main types of opioid receptors
mu delta kappa
Analgesia
Supraspinal +++
Spinal ++
Peripheral ++
Respiratory depression +++
Pupil constriction ++
Reduced GI motility ++
Euphoria +++
Dysophoria -
Sedation ++
Physical dependence +++
-
++
-
++
-
++
-
-
-
-
-
+
++
-
+
+
-
+++
++
+
![Page 28: Lower GI Drugs Katzung (10th ed.) Chapter 63: pg. 1019-1036 Med 5724 Gastrointestinal Hepatobiliary System Winter 2009 Dr. Janet Fitzakerley jfitzake@d.umn.edu](https://reader035.vdocuments.us/reader035/viewer/2022062321/56649e105503460f94afaecc/html5/thumbnails/28.jpg)
2) BABRS: CHOLESTYRAMINE, COLESTIPOL
Mechanism and Uses
![Page 29: Lower GI Drugs Katzung (10th ed.) Chapter 63: pg. 1019-1036 Med 5724 Gastrointestinal Hepatobiliary System Winter 2009 Dr. Janet Fitzakerley jfitzake@d.umn.edu](https://reader035.vdocuments.us/reader035/viewer/2022062321/56649e105503460f94afaecc/html5/thumbnails/29.jpg)
2) BABRS: CHOLESTYRAMINE, COLESTIPOL
Side effects
![Page 30: Lower GI Drugs Katzung (10th ed.) Chapter 63: pg. 1019-1036 Med 5724 Gastrointestinal Hepatobiliary System Winter 2009 Dr. Janet Fitzakerley jfitzake@d.umn.edu](https://reader035.vdocuments.us/reader035/viewer/2022062321/56649e105503460f94afaecc/html5/thumbnails/30.jpg)
3) OCTREOTIDE
Mechanism of action
![Page 31: Lower GI Drugs Katzung (10th ed.) Chapter 63: pg. 1019-1036 Med 5724 Gastrointestinal Hepatobiliary System Winter 2009 Dr. Janet Fitzakerley jfitzake@d.umn.edu](https://reader035.vdocuments.us/reader035/viewer/2022062321/56649e105503460f94afaecc/html5/thumbnails/31.jpg)
3) OCTREOTIDE
Therapeutic Uses
![Page 32: Lower GI Drugs Katzung (10th ed.) Chapter 63: pg. 1019-1036 Med 5724 Gastrointestinal Hepatobiliary System Winter 2009 Dr. Janet Fitzakerley jfitzake@d.umn.edu](https://reader035.vdocuments.us/reader035/viewer/2022062321/56649e105503460f94afaecc/html5/thumbnails/32.jpg)
3) OCTREOTIDE
Side effects
![Page 33: Lower GI Drugs Katzung (10th ed.) Chapter 63: pg. 1019-1036 Med 5724 Gastrointestinal Hepatobiliary System Winter 2009 Dr. Janet Fitzakerley jfitzake@d.umn.edu](https://reader035.vdocuments.us/reader035/viewer/2022062321/56649e105503460f94afaecc/html5/thumbnails/33.jpg)
4) BISMUTH SUBSALICYLATE
Mechanism of action
![Page 34: Lower GI Drugs Katzung (10th ed.) Chapter 63: pg. 1019-1036 Med 5724 Gastrointestinal Hepatobiliary System Winter 2009 Dr. Janet Fitzakerley jfitzake@d.umn.edu](https://reader035.vdocuments.us/reader035/viewer/2022062321/56649e105503460f94afaecc/html5/thumbnails/34.jpg)
4) BISMUTH SUBSALICYLATE
Therapeutic Uses
![Page 35: Lower GI Drugs Katzung (10th ed.) Chapter 63: pg. 1019-1036 Med 5724 Gastrointestinal Hepatobiliary System Winter 2009 Dr. Janet Fitzakerley jfitzake@d.umn.edu](https://reader035.vdocuments.us/reader035/viewer/2022062321/56649e105503460f94afaecc/html5/thumbnails/35.jpg)
4) BISMUTH SUBSALICYLATE
Side effects
![Page 36: Lower GI Drugs Katzung (10th ed.) Chapter 63: pg. 1019-1036 Med 5724 Gastrointestinal Hepatobiliary System Winter 2009 Dr. Janet Fitzakerley jfitzake@d.umn.edu](https://reader035.vdocuments.us/reader035/viewer/2022062321/56649e105503460f94afaecc/html5/thumbnails/36.jpg)
5) ABSORBANTS: KAOLIN, PECTIN
Mechanism and Side Effects
![Page 37: Lower GI Drugs Katzung (10th ed.) Chapter 63: pg. 1019-1036 Med 5724 Gastrointestinal Hepatobiliary System Winter 2009 Dr. Janet Fitzakerley jfitzake@d.umn.edu](https://reader035.vdocuments.us/reader035/viewer/2022062321/56649e105503460f94afaecc/html5/thumbnails/37.jpg)
LAXATIVES and CATHARTICS
![Page 38: Lower GI Drugs Katzung (10th ed.) Chapter 63: pg. 1019-1036 Med 5724 Gastrointestinal Hepatobiliary System Winter 2009 Dr. Janet Fitzakerley jfitzake@d.umn.edu](https://reader035.vdocuments.us/reader035/viewer/2022062321/56649e105503460f94afaecc/html5/thumbnails/38.jpg)
Categories
![Page 39: Lower GI Drugs Katzung (10th ed.) Chapter 63: pg. 1019-1036 Med 5724 Gastrointestinal Hepatobiliary System Winter 2009 Dr. Janet Fitzakerley jfitzake@d.umn.edu](https://reader035.vdocuments.us/reader035/viewer/2022062321/56649e105503460f94afaecc/html5/thumbnails/39.jpg)
1) STOOL SOFTENERS: DOCUSATE, MINERAL OIL
Mechanism of action
![Page 40: Lower GI Drugs Katzung (10th ed.) Chapter 63: pg. 1019-1036 Med 5724 Gastrointestinal Hepatobiliary System Winter 2009 Dr. Janet Fitzakerley jfitzake@d.umn.edu](https://reader035.vdocuments.us/reader035/viewer/2022062321/56649e105503460f94afaecc/html5/thumbnails/40.jpg)
1) STOOL SOFTENERS: DOCUSATE, MINERAL OIL
Therapeutic Uses• despite widespread use, have marginal efficacy in
most cases of constipation • are used clinically for:
o softening of feces in anorectal abnormalities o hernia or cardiovascular disease o hemorrhoids o diverticular disease of the colon o radiological examination of the bowel
![Page 41: Lower GI Drugs Katzung (10th ed.) Chapter 63: pg. 1019-1036 Med 5724 Gastrointestinal Hepatobiliary System Winter 2009 Dr. Janet Fitzakerley jfitzake@d.umn.edu](https://reader035.vdocuments.us/reader035/viewer/2022062321/56649e105503460f94afaecc/html5/thumbnails/41.jpg)
1) STOOL SOFTENERS: DOCUSATE, MINERAL OIL
Contraindications
![Page 42: Lower GI Drugs Katzung (10th ed.) Chapter 63: pg. 1019-1036 Med 5724 Gastrointestinal Hepatobiliary System Winter 2009 Dr. Janet Fitzakerley jfitzake@d.umn.edu](https://reader035.vdocuments.us/reader035/viewer/2022062321/56649e105503460f94afaecc/html5/thumbnails/42.jpg)
1) STOOL SOFTENERS: DOCUSATE, MINERAL OIL
Side effects
MINERAL OIL may result in severe lipid pneumonitis if aspirated; long term use can cause decreased absorption of fat soluble vitamins.
![Page 43: Lower GI Drugs Katzung (10th ed.) Chapter 63: pg. 1019-1036 Med 5724 Gastrointestinal Hepatobiliary System Winter 2009 Dr. Janet Fitzakerley jfitzake@d.umn.edu](https://reader035.vdocuments.us/reader035/viewer/2022062321/56649e105503460f94afaecc/html5/thumbnails/43.jpg)
2) STOOL SOFTENERS:DIETARY FIBRE, METHYLCELLULOSE, PSYLLIUM
Mechanism of action
![Page 44: Lower GI Drugs Katzung (10th ed.) Chapter 63: pg. 1019-1036 Med 5724 Gastrointestinal Hepatobiliary System Winter 2009 Dr. Janet Fitzakerley jfitzake@d.umn.edu](https://reader035.vdocuments.us/reader035/viewer/2022062321/56649e105503460f94afaecc/html5/thumbnails/44.jpg)
2) STOOL SOFTENERS:DIETARY FIBRE, METHYLCELLULOSE, PSYLLIUM
Side effects
![Page 45: Lower GI Drugs Katzung (10th ed.) Chapter 63: pg. 1019-1036 Med 5724 Gastrointestinal Hepatobiliary System Winter 2009 Dr. Janet Fitzakerley jfitzake@d.umn.edu](https://reader035.vdocuments.us/reader035/viewer/2022062321/56649e105503460f94afaecc/html5/thumbnails/45.jpg)
3) CONTACT CATHARTICS:ANTHRAQUINONE DERIVATIVES (Cascara sagrada*,
Danthron, Senna), BISACODYL, CASTOR OIL Mechanisms of action
BISACODYL and ANTHRAQUINONES act on the large intestine and are less potent. CASTOR OIL acts on both the small and large intestine short latency and extremely potent effects --- as well as more significant side effects.
![Page 46: Lower GI Drugs Katzung (10th ed.) Chapter 63: pg. 1019-1036 Med 5724 Gastrointestinal Hepatobiliary System Winter 2009 Dr. Janet Fitzakerley jfitzake@d.umn.edu](https://reader035.vdocuments.us/reader035/viewer/2022062321/56649e105503460f94afaecc/html5/thumbnails/46.jpg)
3) CONTACT CATHARTICS:ANTHRAQUINONE DERIVATIVES (Cascara sagrada*,
Danthron, Senna), BISACODYL, CASTOR OIL Side effects
![Page 47: Lower GI Drugs Katzung (10th ed.) Chapter 63: pg. 1019-1036 Med 5724 Gastrointestinal Hepatobiliary System Winter 2009 Dr. Janet Fitzakerley jfitzake@d.umn.edu](https://reader035.vdocuments.us/reader035/viewer/2022062321/56649e105503460f94afaecc/html5/thumbnails/47.jpg)
4) OSMOTIC (SALINE) CATHARTICS:LACTULOSE, LUBIPROSTONE, MAGNESIUM HYDROXIDE, SODIUM PHOSPHATE, POLYETHYLENE GLYCOL (see GI decontamination handout)
Mechanisms of Action
![Page 48: Lower GI Drugs Katzung (10th ed.) Chapter 63: pg. 1019-1036 Med 5724 Gastrointestinal Hepatobiliary System Winter 2009 Dr. Janet Fitzakerley jfitzake@d.umn.edu](https://reader035.vdocuments.us/reader035/viewer/2022062321/56649e105503460f94afaecc/html5/thumbnails/48.jpg)
4) OSMOTIC (SALINE) CATHARTICS:LACTULOSE, LUBIPROSTONE, MAGNESIUM HYDROXIDE, SODIUM PHOSPHATE, POLYETHYLENE GLYCOL (see GI decontamination handout)
Therapeutic Uses
![Page 49: Lower GI Drugs Katzung (10th ed.) Chapter 63: pg. 1019-1036 Med 5724 Gastrointestinal Hepatobiliary System Winter 2009 Dr. Janet Fitzakerley jfitzake@d.umn.edu](https://reader035.vdocuments.us/reader035/viewer/2022062321/56649e105503460f94afaecc/html5/thumbnails/49.jpg)
4) OSMOTIC (SALINE) CATHARTICS:LACTULOSE, LUBIPROSTONE, MAGNESIUM HYDROXIDE, SODIUM PHOSPHATE, POLYETHYLENE GLYCOL (see GI decontamination handout)
Mechanisms of Action
All osmotic laxatives can cause intravascular volume depletion and electrolyte imbalances, esp.reduced potassium concentrations (therefore contraindicated in patients who are frail, elderly, have renal insufficiency or have significant cardiac disease).
![Page 50: Lower GI Drugs Katzung (10th ed.) Chapter 63: pg. 1019-1036 Med 5724 Gastrointestinal Hepatobiliary System Winter 2009 Dr. Janet Fitzakerley jfitzake@d.umn.edu](https://reader035.vdocuments.us/reader035/viewer/2022062321/56649e105503460f94afaecc/html5/thumbnails/50.jpg)
Use and Abuse ofLaxatives and Cathartics
• the overwhelming majority of people do not need laxatives, yet they are self-prescribed by a large portion of the general population
• prescription of laxatives should be secondary to fiber-rich diet, adequate fluid intake, physical activity, with milder laxatives (such as bulk-forming laxatives) being the first choice
• use lowest effective dosage, as infrequently as possible, and discontinue as soon as possible
• patients can become totally reliant on a daily dose (cathartic colon), although recent research suggests that this is quite rare